Abstract

Given the prevalence of chronic wounds and soft tissue defects, which are associated with major complications such as persistent inflammation, poor vascularization, infection risk, and delayed tissue remodeling, there is a need for new materials that can overcome these limitations. Fibrin-based materials have attracted researchers’ attention for their roles in hemostasis and wound healing, as well as their biocompatibility, biodegradability, and ability to mimic the extracellular matrix. Regarding the clinical applicability of fibrin-based materials, they are currently available on the market as fibrin sealants. However, efforts are underway to improve their properties by developing hydrogels, platelet-derived fibrin matrices, and composite scaffolds that enhance mechanical stability, bioactivity, and the controlled release of cells or therapeutic agents. In addition, the number of clinical studies and registered clinical trials reflects interest in the potential applicability of fibrin-based materials in medical applications. However, the available clinical evidence remains limited for many emerging systems, and further validation is required. Although significant limitations remain, including rapid degradation, variable mechanical strength, and the need for standardized manufacturing processes, recent advances in hybrid systems and biofabrication technologies suggest promising future potential for personalized regenerative therapies.

IPC Classification

Keywords